Late-onset genetic cholestasis is a rare and often under-recognized condition, leading to delayed or missed diagnoses. Existing resources primarily focus on pediatric cases, leaving gaps in awareness about the less severe and varied symptoms that can appear into adulthood.
This expert-led program will allow you to effectively recognize and diagnose late-onset genetic cholestasis, and make informed decisions on individualized patient management strategies, by providing education on disease presentation, the importance of genetic testing, symptom management, clinical guidelines, and new advances in the treatment landscape.
Latest content
Learning objectives
Following completion of this independent educational program, you will be able to:
- Recognize the different phenotypes and clinical presentations of late-onset genetic cholestasis
- Integrate consensus recommendations and diagnostic tools to accurately diagnose different types of late-onset genetic cholestasis
- Debate best practice for the current and potential future management of different forms of late-onset genetic cholestasis
Meet the faculty

Dr Richard Thompson
Professor of Molecular Hepatology, Kings College London, United Kingdom
Dr Thompson specialises in paediatric liver disease. In particular he is interested in genetic disease, both in children and adults. His group have identified several disease genes, and have established important genotype/pehotype correlations. He is also the Clinical Lead for the Liver Molecular Genetics service.Disclosures
Honoraria or consultation fees: CymaBay, Enanta, Genfit, GSK, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, 89bio, Zydus, Abbvie, Intercept, Gilead Honoraria or consultation fees: Mirum, Ipsen, Rectify, Generation Bio, Integra, Spruce, Alnylam, Glycomine Stocks, shares or equity: Generation Bio, Rectify, Integra
Dr Verena Keitel-Anselmino
Clinic of Gastroenterology, Hepatology, and Infectiology Project Leader, Otto von Geuricke University Magdeburg, Germany
Verena Keitel-Anselmino received her training in gastroenterology and hepatology at Dusseldorf University Hospital. Since September 2021 she has been the head of the Department of Gastroenterology, Hepatology and Infectious Diseases at Magdeburg University Hospital. Her clinical and research interests lie in the field of autoimmune and cholestatic liver diseases with a special emphasis on hereditary cholestasis.Disclosures
Honoraria or consultation fees: Mirum, GSK, Albireo/Ipsen, Falk, AstraZenecaStocks, shares or equity: Madrigal
Participation in a company sponsored speaker bureau: Falk, AstraZeneca, Ipsen, Mirum, Albireo, GSK, Gilead, MSD

Miki Scaravaglio
Department of Medicine and Surgery, University of Milano-Bicocca, Italy
Academic Clinical Fellow in Hepatology with a special interest in autoimmune and cholestatic liver disease based at the University of Milano-Bicocca, Italy.Disclosures
None to declare
Silvia Vilarinho
Yale University, USA
Silvia Vilarinho is a physician-scientists with an overarching career goal to bridge patient care to disease-relevant research. Nearly all studies in her laboratory begin with patients with liver disease of unclear etiology. She utilizes human genetics and genomics to investigate the molecular mechanism(s) underlying liver disease in these patients with potential diagnostic, therapeutic and prognostic applications. Her research group uses cell-based and mouse models to determine the specific mechanism(s) linking mutant gene to disease. This research approach provides new knowledge with direct impact in improving patient care and creates an outstanding scientific environment to train future physician-scientists and trainees with particular interest in human disease. Furthermore, Silvia is very committed to make ‘genomic medicine for liver disease’ a reality in clinical practice worldwide.Disclosures
Honoraria or consultation fees: Alberio, Ipsen, Mirum Grants/research support: Moderna
Deepak Joshi
Kings College Hospital NHS Foundation Trust, United Kingdom
Dr Deepak Joshi is a transplant hepatologist with an interest in autoimmune liver disease. He is the clinical lead for HPB medicine and an advanced biliary endoscopist, specialising in paediatrics. He is a member of the Young Adult Liver service at King’s working in a multi-disciplinary team. He is a Reader in HPB medicine at King’s College London. He is a co-author of the book, Hepatology at a Glance. His current research interests include the management of biliary disease pre- and post-liver transplantation including the role of endoscopy.Disclosures
Honoraria or consultation fees: Ipsen Pharma, Mirum, Boston Scientific, Q3 MedicalTarget audience
This program is primarily aimed at a global audience of adult hepatologists and gastroenterologists, but is relevant to all members of the multidisciplinary team that manages late-onset genetic cholestatic patients.
Planning committee
In addition to the expert faculty Springer Healthcare IME planners and staff include Rachel Goddard, Rebecca Cox, and Lynda Williams. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.